Experienced in Adrenocortical Carcinoma

Dr. Sunandana Chandra

Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 4 Trials
Offers Telehealth
18 Years of Experience
Experienced in Adrenocortical Carcinoma
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sunandana Chandra is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Chandra has been practicing medicine for over 18 years and is rated as an Experienced provider by MediFind in the treatment of Adrenocortical Carcinoma. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, and Neuroendocrine Tumor.

Her clinical research consists of co-authoring 115 peer reviewed articles and participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 1 clinical trial in the study of Adrenocortical Carcinoma.

Graduate Institution
Michigan State University College Of Human Medicine, 2008.0
Residency
Case Western Reserve University/University Hospitals Cleveland Medical Center
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NY
Board Certifications
American Board Of Internal Medicine - Medical Oncology (Certified)
Fellowships
NYU Grossman School of Medicine
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Palos Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

675 N St Clair St Ste 21-100, Galter Pavilion, Chicago, IL 60611

Additional Areas of Focus

Dr. Chandra has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

24 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy
Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Tazemetostat Hydrobromide, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Drug, Biological
Study Drugs: Binimetinib, Encorafenib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors
Enrollment Status: Recruiting
Publish Date: March 26, 2025
Intervention Type: Biological
Study Drugs: VV1, Cemiplimab
Study Phase: Phase 2
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Biological
Study Drugs: Bevacizumab, Ipilimumab
Study Phase: Phase 2
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Other, Drug
Study Drug: Avelumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Biological, Procedure, Other
Study Drugs: Nivolumab, Talimogene Laherparevec
Study Phase: Phase 2
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Pembrolizumab
Study Phase: Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
A Multi-Center Phase II Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
A Multi-Center Phase II Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine
Study Phase: Phase 2
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Enrollment Status: Completed
Publish Date: June 12, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Nivolumab, Veliparib
Study Phase: Phase 1
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Enrollment Status: Unknown
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma
Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: January 25, 2022
Intervention Type: Radiation, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 1
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
Enrollment Status: Terminated
Publish Date: July 16, 2020
Intervention Type: Biological, Other
Study Phase: Phase 2
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Enrollment Status: Terminated
Publish Date: May 01, 2019
Intervention Type: Other, Drug
Study Phase: Phase 2
View 20 Less Clinical Trials

115 Total Publications

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
Journal: Future oncology (London, England)
Published: October 15, 2025
Similar Doctors
Young K. Chae
Advanced in Adrenocortical Carcinoma
Dr. Young K. Chae
Hematology | Oncology
Advanced in Adrenocortical Carcinoma
Dr. Young K. Chae
Hematology | Oncology
233 E Superior St 1st Fl, Olson Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Young Chae is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Chae has been practicing medicine for over 24 years and is rated as an Elite provider by MediFind in the treatment of Adrenocortical Carcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

Veerpal Singh
Advanced in Adrenocortical Carcinoma
Dr. Veerpal Singh
Hematology | Oncology
Advanced in Adrenocortical Carcinoma
Dr. Veerpal Singh
Hematology | Oncology

Illinois Cancer Specialists

1710 N Randall Rd, 
Elgin, IL 
 (39.2 miles away)
847-931-0909
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Veerpal Singh is a Hematologist and an Oncologist in Elgin, Illinois. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Adrenocortical Carcinoma. His top areas of expertise are Gallbladder Cancer, Colorectal Cancer, Lynch Syndrome, Gallbladder Adenocarcinoma, and Bone Marrow Aspiration.

Devalingam Mahalingam
Experienced in Adrenocortical Carcinoma
Dr. Devalingam Mahalingam
Hematology | Oncology
Experienced in Adrenocortical Carcinoma
Dr. Devalingam Mahalingam
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
26+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Devalingam Mahalingam is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Mahalingam has been practicing medicine for over 26 years and is rated as a Distinguished provider by MediFind in the treatment of Adrenocortical Carcinoma. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Colorectal Cancer, and Liver Embolization.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chandra's expertise for a condition
ConditionClose
View All 58 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile